Dr. Pirone said it may be easier to move for total exemptions at 
a later date. Dr. Fedor off pointed out that when the subgroup on 
plants had started working, they had an objective to exempt as 
much as possible from the NIH Guidelines. However, the subgroup 
had decided it was more important to loosen restrictions on what 
could be done than to exempt things. She said it is not that 
these experiments should not be exempted, but it would be prefer- 
able to take this in two stages. 
Mr. Mitchell requested that rather than get into a lengthy 
discussion on this topic, the committee adjourn for lunch and 
reconvene in one hour. Whereupon, the committee adjourned for 
lunch to continue its deliberations at 1:20 p.m. the same day. 
Mr. Mitchell called the committee back to order at 1:20 p.m. He 
noted persons who were interested in purchasing copies of the 
transcript of today's hearing could place their orders with the 
official reporter. He also announced that Science had recently 
devoted a large amount of space to the 100th Anniversary of the 
National Institutes of Health and informed committee members that 
there would be a series of events in October 1987 which they may 
wish to attend. 
Mr. Mitchell said some concern had been expressed pertaining to 
experiments conducted by Dr. Gary Strobel of Montana State 
University dealing with elm trees, and whether he had violated 
the NIH Guidelines in these experiments. He noted that 
Dr. Wyngaarden, Director, NIH, had appointed a committee to look 
into this matter. He asked Dr. Vidaver if she wished to comment 
on this matter. 
Dr. Vidaver said that she was brought in as an outside consultant 
to Montana State University. The NIH committee had made 
recommendations to Dr. Wyngaarden on the experiment in question 
as to whether Dr. Strobel had a recombinant organism or not. She 
added that it would be premature to discuss the committee ' s 
findings at this point other than to say that the committee had 
found that the organism in question was not recombinant. 
Mr. Mitchell said he had brought this up as an informational 
item. He assumed the matter was still under review, and he 
assumed that a report would be forthcoming from the Office of the 
Director, NIH. 
Mr. Mitchell then reminded the committee that a motion was 
pending on the floor as made by Dr. Gottesman. Dr. Walters then 
called the question on the motion. 
Dr. Gartland asked for clarification as to whether the motion 
included repeating paragraph 34 at the beginning of paragraph 184 
or merely blending this text into 184 in some way. 
Dr. Gottesman said she believed it should follow 184. Dr. 
[ 66 ] 
Recombinant DNA Research, Volume 13 
